Discontinued Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 25, 2020	Dec. 27, 2019	Nov. 04, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Tax Effect of Discontinued Operation	$ (5.0)	$ (16.2)	$ 1.7
Losses (gains) on divestiture	0.8	(16.6)	33.5
Equity Certificates Redeemed Amount		29.8
(Benefit) expense from income taxes	(106.3)	8.9	(584.3)
Nuclear Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax		9.0	9.0
Contingent consideration received, equity certificates		9.0	9.0
Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, Net of Tax		$ 32.5
Interest Rate, Equity Certificates		10.00%
(Benefit) expense from income taxes	$ 5.1	$ 18.1
Interest and Other Income		2.7
BioVectra Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Consideration				$ 250.0
Disposal Group, Including Discontinued Operation, Upfront Consideration				135.0
Disposal Group, Not Discontinued Operation, Contingent Consideration				$ 115.0
Losses (gains) on divestiture			$ 33.5
Hemostasis Products
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Losses (gains) on divestiture		$ (16.5)